Immunogen (IMGN) Tops Q4 EPS by 1c

February 9, 2018 6:32 AM

Immunogen (NASDAQ: IMGN) reported Q4 EPS of ($0.11), $0.01 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $39.45 million versus the consensus estimate of $32.71 million.

Financial Guidance

For 2018, ImmunoGen expects:

For earnings history and earnings-related data on Immunogen (IMGN) click here.


Earnings Guidance

Next Articles